Hanna Bandos, PhD, Promoted to Research Associate Professor at the University of Pittsburgh

08/06/2026

In May 2026, Dr. Hanna Bandos was promoted to Research Associate Professor of Biostatistics and Health Data Science at the University of Pittsburgh. Dr. Bandos first joined NSABP in 2007 as a protocol statistician and has since contributed to more than 20 clinical trials. Among her most notable contributions to the breast cancer treatment trials are her work on the effectiveness of extended adjuvant letrozole following aromatase inhibitor-based therapy in postmenopausal patients with ER-positive breast cancer (NSABP B-42), and her involvement in investigating the role of regional radiation in patients whose lymph nodes tested negative after neoadjuvant treatment and surgery (NSABP B-51). Dr. Bandos also serves as a statistician for several quality-of-life (QOL) studies. One of her recent pivotal collaborations was on the QOL sub-study of OlympiA/NSABP B-55, a landmark phase III clinical trial that led to the FDA approval of Olaparib© for the adjuvant treatment of patients with BRCA1- or BRCA2-mutated breast cancer.

In her current roles, Dr. Bandos serves as the lead statistician for the prevention subcommittee of the NRG Oncology Cancer Prevention and Control Committee and as protocol statistician for FORTE (NRG-CC005), a Phase III clinical trial seeking to enroll 9,500 participants to identify the optimal colonoscopy surveillance schedule for colorectal cancer prevention. She also holds the position of Statistical Editor at the Journal of the National Cancer Institute (JNCI) and served on the NCI Breast Oncology Local Disease (BOLD) and Head and Neck Met-Rec Task Forces and as an ad-hoc member of the NCI Molecular Cancer Diagnosis and Classification Study Section. She actively contributes to the academic program of the Department by developing and teaching courses, advising students, and serving on departmental committees.